GPR17 modulates anxiety-like behaviors basolateral amygdala to ventral hippocampal CA1 glutamatergic projection.

Anxiety disorders are one of the most epidemic and chronic psychiatric disorders. An incomplete understanding of anxiety pathophysiology has limited the development of highly effective drugs against these disorders. GPR17 has been shown to be involved in multiple sclerosis and some acute brain injury disorders.